LONDON (dpa-AFX) - The U.S. Food and Drug Administration approved
AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu
(fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with
unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received
prior systemic treatment and have no satisfactory alternative treatment options.

The indication is approved under accelerated approval based on objective
response rate and duration of response. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in a
confirmatory trial.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC)
discovered by Daiichi Sankyo and being jointly developed and commercialized by
AstraZeneca and Daiichi Sankyo.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX